Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
|Articles|October 1, 2007
- Volume 0 0
diabetes PRODUCT charts
Advertisement
Articles in this issue
about 19 years ago
Actemra Found to Relieve RA Symptomsabout 19 years ago
Zestra Reports Positive Results of OTC Feminine Arousal Fluidabout 19 years ago
Trial of New Weight-loss Pill Leaves Patients Feeling Fullabout 19 years ago
Oral Care Products and the Diabetic Patientabout 19 years ago
FOLIC ACID REDUCES RISK OF STROKEabout 19 years ago
FDA APPROVES UPDATED WARFARIN INFOabout 19 years ago
FONDAPARINUX MAY BE OPTION FOR HITabout 19 years ago
Hyperthermia, Chemotherapy Aid High-risk Cancer Patientsabout 19 years ago
High Blood Pressure: Getting the Most Out of Home Monitoringabout 19 years ago
can you READ these Rxs?Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
4
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
5